SkyePharma annual report 2002 Consolidated statement of total recognised gains and losses Year to Year to 31 December 2002 31 December 2001 000 000 Profit loss attributable to shareholders 1,109 9,452 Net currency translation effect 903 28 Lapse of warrants 1,096 271 Total recognised gains and losses for the year 3,108 9,153 As described in note 22a: Share Capital, the B Warrants relating to the acquisition of Krypton lapsed on 31 December 2002.
The fair value of the lapsed warrants of 1,096,000 has been transferred from non-distributable reserves to retained profits.
In 2001 the class C Warrants relating to the debenture issue lapsed.
The fair value of the warrants at issue of 271,000 was transferred from non-distributable reserves to retained profits.
The lapse of warrants represents a transfer of value from the warrant holders to existing shareholders.
In accordance with FRS4: Capital instruments, this is shown as a recognised gain, although total shareholders funds remain unchanged.
Reconciliation of movements in shareholders funds Year to Year to 31 December 2002 31 December 2001 000 000 Shareholders funds at the beginning of the year 95,145 68,952 Total recognised gains and losses for the year 3,108 9,153 Goodwill adjustments on deferred consideration 4,837 148 Equity shares issued allocated, net of expenses 43,816 29,599 Exercise of share options, net of expenses 700 459 Non-equity shares converted to equity shares 11,310 Decrease increase in shares and warrants to be issued 5,780 5,780 Revaluation of shares and warrants to be issued 4,837 148 Issue of warrants 311 Exercise of warrants 624 56 Lapse of warrants 1,096 436 Net movement in the year 29,125 26,193 Shareholders funds at the end of the year 124,270 95,145 consolidated statement of total 51 recognised gains and losses reconciliation of movements in shareholders funds
